HOOOOOOOLD YOUR SHARES...Today will be 3 months since the initiation of the combo trial for the melanoma ....hope we get some good news the very soon...someone may be trying to steel our shares cheap....also it is 7 months from the lung cancer trial....
Thats a big yes to FCEL future..hell with Alon.
Kim Sherman was in bad shape a year ago after a lemon-sized melanoma tumor in her pelvis stopped responding to standard targeted therapy. By late June 2013, the pain from the mass pressing on her hamstring became so bad she could hardly sleep, walk, or even sit down.
Then she joined a trial on an experimental drug from Bristol-Myers Squibb Co. designed to boost the immune system against her tumor when used in combination with the company’s existing immune enhancing drug Yervoy. Within three weeks the pain started to subside, and within three months later the tumor disappeared. Her doctor at Yale Cancer Center in New Haven may stop therapy entirely in a few weeks, she said.
“I was ecstatic. I had the best possible result,” said Sherman, a 48-year-old mother of three from Buchanan, New York. “This is a pretty remarkable drug combination.”
At the American Society of Clinical Oncology meeting in Chicago, results like this are raising hopes that new immune system-boosting medicines can produce long survival in numerous advanced tumors, at least for those who respond to the drugs.
In Sherman’s trial, 79 percent of an initial group of 53 patients who received the experimental medicine nivolumab combined with Yervoy were still alive after two years, a better result than is seen with existing drugs for advanced melanoma.
In another study of 411 advanced melanoma patients who got Merck & Co.’s drug, called MK-3475, 62 percent were alive 18 months after starting treatment, according to results being released at the meeting. Merck has already applied for U.S. Food and Drug Administration marketing approval based on the results, with a decision
I do not disagree however, progress is slow and they are just repeating old things of HIV, HCV and imaging etc..Is there a committee to have a milestones review ...???? thats a concern to me...
Also no Vol increase with the development of Phase-III...
GALT will be an advance NASH treatment.
The New England Journal of Medicine (July 11, 2013). In their study, Wolchok and collagues (2013) treated 53 patients concurrently, and 33 patients sequentially with nivolumab and ipilimumab. Rapid responses were observed in concurrent-regimen cohorts as compared with sequential-regimen cohorts. The objective response rate in the concurrent-regimen cohorts was 40% along with 53% patients exhibited tumor regression of 80% or more. The objective response rate in the sequenced-regimen cohorts was 20% and 13% patients had tumor regression of 80% or more. In both groups, treatment related adverse events were managed with the use of immunosuppressants.
We are amazed at the results that we see with PD-1 blockade.[7-9] Both of us have a lot of experience with this antibody, and we have the feeling that we see a level of response that is quite close to what we see with targeted agents -- a lot of patients responding: 30% to 40%. And although we have less follow-up than we have with the drugs that are on the market, we have the feeling that we are seeing long-term responses, and the side effects are not bad. Now we think that it can be combined with an anti-cytotoxic T-lymphocyte antigen 4 (anti-CTLA-4) agent for an even higher level of response, so there is so much hope for our patients. These drugs are now being evaluated in phase 3 trials, and we hope that they are going to be developed very rapidly.
Today we had the poster with the follow-up data on the combination of ipilimumab, an anti-CTLA-4 blocking antibody, and nivolumab, a PD-1 antibody. They had a very high rate of objective responses, more than 50% in the dosing regimen that is taken forward, with most responses continuing on. It's indirectly suggesting that we are getting higher with antitumor activity with immunotherapies, but we are getting the benefit of durable responses. A couple of years ago I would not have guessed that we would be talking about this level of activity with antibodies that modulate the immune system but do not do anything to the cancer, and the immune system is doing the job.